Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 2, 2004, Pages 198-205

  Carmo, Helena ^a   Hengstler, Jan G ^b   De Boer, Douwe ^c   Ringel, Michael ^b   Carvalho, Félix ^a   Fernandes, Eduarda ^a   Remião, Fernando ^a   Dos Reys, Lesseps A ^c   Oesch, Franz ^c   Bastos, Maria De Lourdes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Laboratory of Doping Control   (Portugal)

Author keywords

4 Methylthioamphetamine; Cryopreserved hepatocytes; Designer drugs; In vitro; Metabolism

Indexed keywords

4 METHYLTHIOAMPHETAMINE; 4 METHYLTHIOBENZOIC ACID; ADENOSINE TRIPHOSPHATE; AMPHETAMINE DERIVATIVE; BENZOIC ACID DERIVATIVE; DESIGNER DRUG; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; DOG; GAS CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MALE; MASS SPECTROMETRY; MONKEY; MOUSE; NONHUMAN; RABBIT; RAT; SPECIES DIFFERENCE;

AMPHETAMINES; ANIMALS; BENZOIC ACIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HEPATOCYTES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MIDDLE AGED; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TIME FACTORS;

EID: 10744225635     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-003-0850-0     Document Type: Article

References (23)

1. Andreu V, Mas A, Bruguera M, Salmeron JM, Moreno V, Nogue S, Rodes J (1998) Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 29:394-397
2. Caldwell J (1980) The metabolism of amphetamines and related stimulants in animals and man. In: Caldwell J (ed) Amphetamines and related stimulants: chemical, biological, clinical, and sociological aspects. CRC, Boca Raton, pp 29-46
3. Carmo H, de Boer D, Remião F, Carvalho F, Reys LA, Bastos ML (2002) Identification of 4-methylthioamphetamine and some of its metabolites in mouse urine by GC-MS after acute administration. J Anal Toxicol 26:228-232
4. Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281-1289
5. De Boer D, Egberts T, Maes RA (1999) Para-methylthioamphetamine, a new amphetamine designer drug of abuse. Pharm World Sci 21:47-48
6. De Letter EA, Coopman VA, Cordonnier JA, Piette MH (2001) One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int J Legal Med 114:352-356
7. Elliott SP (2000) Fatal poisoning with a new phenethylamine: 4-methylthioamphetamine (4-MTA). J Anal Toxicol 24:85-89
8. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (1999) Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs. European Monitoring Centre for Drugs and Drug Addiction, Luxembourg
9. Fritz G, Hengstler JG, Kaina B (1997) High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines. Cancer Res 57:454-460
10. Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B (1999) Contribution of c-erbB-2 and topoisomerase lia to chemoresistance in ovarian cancer. Cancer Res 59:3206-3214
11. Hengstler JG, Ringel M, Biefang K, Hammel S, Milbert U, Gerl M, Klebach M, Diener B, Platt KL, Böttger T, Steinberg P, Oesch F (2000a) Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chem Biol Interact 125:51-73
12. Hengstler JG, Utesch D, Steinberg P, Ringel M, Swales N, Biefang K, Platt KL, Diener B, Böttger T, Fischer T, Oesch F (2000b) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32:81-118
13. Huang X, Marona-Lewicka D, Nichols DE (1992) p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229:31-38
14. Jones AL, Simpson KJ (1999) Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 13:129-133
15. Jones AL, Jarvie DR, McDermid G, Proudfoot AT (1994) Hepatocellular damage following amphetamine intoxication. J Toxicol Clin Toxicol 32:435-444
16. Kavanagh PV, Corrigan D, Maguire RT, Meegan MJ, Keating JJ, Clancy J, Burdett J (1999) Excretion profile of 4-methylthioamphetamine in dogs. Pharm Pharmacol Commun 5:653-655
17. Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD (1996) Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino) butane (MBDB), 5-methoxy-6-methyl-2- aminoindan (MMAI) and p-methylthioamphetamine (MTA). J Pharmacol Exp Ther 279:1261-1267
18. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti Rats. Pharmacol Biochem Behav 64:29-34
19. Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M (1997) Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Biochem Pharmacol 54:1361-1369
20. Sporer KA (1995) The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf 13:94-104
21. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TY (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156
22. Winstock AR, Wolff K, Ramsey J (2002) 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend 67:111-115
23. World Health Organization (2001) WHO Expert Committee on Drug Dependence. Thirty-second report. World Health Organ Tech Rep Ser 903:1-26